Abstracts Archive - Page 2251 of 2425 - ACR Meeting Abstracts

Abstract Number: 2575 • 2012 ACR/ARHP Annual Meeting
Inhibition of Pathogenic Autoantibodies by Accelerating the Exit of Germinal Center B Cells Via Manipulation of Regulator of G-Protein Signaling
John D. Mountz¹, John H. Wang², James S. New³, PingAr Yang⁴, Qi Wu⁴, Bao Luo⁵, Jun Li⁶, Kirk M. Druey⁷ and Hui-Chen Hsu⁴, ¹Dept of Med/Rheumatology Div, Univ of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, ²Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, ³Grad Sch - Biomed Sciences, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD
Background/Purpose: Regulator of G-protein Signaling (RGS) plays a key role in inhibiting chemokine signaling by desensitizing G-protein coupled receptor signals. RGS13 and RGS16 are two…
Abstract Number: 2576 • 2012 ACR/ARHP Annual Meeting
Production of Citrullinated Filaggrin-Specific IgG in Rheumatoid Arthritis Patients Is Associated with an Expansion of Citrullinated Filaggrin Tetramer-Binding Switched Memory Blood B Cells
Philip Titcombe¹, Laura O. Barsness¹, Lauren Giacobbe¹, Emily Baechler Gillespie¹, Erik J. Peterson² and Daniel L. Mueller², ¹University of Minnesota Medical School, Minneapolis, MN, ²Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: Rheumatoid Arthritis (RA) is highly associated with the production of autoantibodies, including rheumatoid factors and anti-citrullinated protein antibodies (ACPA). It remains uncertain whether production…
Abstract Number: 2577 • 2012 ACR/ARHP Annual Meeting
Characterization of Circulating Human B Cells That Bind Cyclic Citrullinated Peptide Antigens in Clinically Active Rheumatoid Arthritis
Gregg J. Silverman¹, John Jung², Jeffrey D. Greenberg³, Adam J. Pelzek⁴, Caroline Gronwall⁵ and Jaya Vas⁵, ¹Medical and Pathology, NYU School of Medicine, New York, NY, ²School of Medicine, NYU, New York, NY, ³New York Hospital for Joint Disease, New York, NY, ⁴School of Medicine, NYU School of Medicine, New York, NY, ⁵Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) were first identified based on their high specificity for RA and now are commonly used as a diagnostic tool. Yet,…
Abstract Number: 2578 • 2012 ACR/ARHP Annual Meeting
Monoclonal IgG Antibodies (ACPAs) From Synovial Fluid B Cells of Rheumatoid Arthritis Patients – Antigen-Driven Affinity Maturation and Cross Reactivity
Khaled Amara¹, Johanna Steen², Fiona Murray², Henner Morbach³, Blanca Fernandez-Rodriguez⁴, Vijay Balasingh², Marianne Engström², Omri Snir², Lena Israelsson⁵, Anca Catrina², Hedda Wardemann⁶, Davide Corti⁴, Eric Meffre Sr.³, Lars Klareskog⁷ and Vivianne Malmström⁸, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, ²Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Department of Immunobiology, Yale University School of Medicine, New Haven, CT, ⁴Institute for Research in Biomedicine, Bellinzona, Switzerland, ⁵Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁶Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Antibodies targeting citrullinated proteins (ACPA) are commonly found in patients with Rheumatoid Arthritis (RA), strongly associate with distinct HLA-DR alleles and predict a more…
Abstract Number: 2579 • 2012 ACR/ARHP Annual Meeting
Novel Autoantibodies to 14-3-3 Eta Are Highly Specific for Rheumatoid Arthritis
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, Vivian P. Bykerk⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Serum 14-3-3 eta, a protein biomarker that is differentially expressed in rheumatoid arthritis (RA), has been reported to add incrementally to rheumatoid factor (RF)…
Abstract Number: 2580 • 2012 ACR/ARHP Annual Meeting
Marginal Zone Defects in Wiskott-Aldrich Syndrome Are Dependent On B Cell Intrinsic Toll-Like Receptor Signals
Shaun W. Jackson¹, Nikita Kolhatkar², Marc A. Schwartz², Socheath Khim¹ and David J. Rawlings³, ¹Seattle Children's Research Institute, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³Pediatrics/Immunology, Washington, Seattle, WA
Background/Purpose: Patients with the primary immunodeficiency Wiskott-Aldrich syndrome (WAS) have severe abnormalities in splenic marginal zone (MZ) anatomy and function. Consistent with this, WAS patients…
Abstract Number: 2581 • 2012 ACR/ARHP Annual Meeting
Anti- Citrullinated Protein Antibodies but Not Rheumatoid Factor Are Associated with Larger Bone Erosions in rheumatoid arthritis patients- a Cross-Sectional Micro Computed Tomography Study
Carolin Hecht¹, Stephanie Finzel¹, Matthias Englbrecht¹, Sarah Schmidt¹, Juergen Rech², Elizabeth Araujo¹ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti- citrullinated protein antibodies (ACPA) are known to be associated with joint destruction and a more severe disease course in rheumatoid arthritis (RA) patients.…
Abstract Number: 2582 • 2012 ACR/ARHP Annual Meeting
Bone Anabolic Changes Progress in Psa Patients Despite Treatment with Methotrexate or Tumour Necrosis Factor Inhibitors
Stephanie Finzel¹, Sebastian Kraus¹, Sarah Schmidt¹, Axel J. Hueber², Juergen Rech³, Klaus Engelke⁴, Matthias Englbrecht¹ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Institute of Medical Physics, University of Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: To investigate whether methotrexate (MTX) or tumour necrosis factor inhibition (TNFi) affect osteophyte formation in patients with psoriatic arthritis (PsA). Methods: 41 patients with…
Abstract Number: 2583 • 2012 ACR/ARHP Annual Meeting
Bone Structure and Perfusion Quantification of Bone Marrow Edema and Pannus Tissue Areas in the Wrist of Patients with RA
Jose R. Teruel Antolin¹, Andrew J. Burghardt², Julien Rivoire¹, Waraporn Srikhum¹, Susan M. Noworolski³, Thomas M. Link¹, John B. Imboden⁴ and Xiaojuan Li⁵, ¹Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ²Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ³Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA, ⁵Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA
Background/Purpose: Bone marrow edema (BME) has been suggested as a strong predictor for erosive progression in RA joints, however, no previous studies examined the bone…
Abstract Number: 2584 • 2012 ACR/ARHP Annual Meeting
Quantitative and Semi-Quantitative Bone Erosion Assessment On High-Resolution Peripheral Quantitative Computed Tomography in Rheumatoid Arthritis
Waraporn Srikhum¹, Warapat Virayavanich¹, Andrew J. Burghardt², Andrew Yu¹, Thomas M. Link¹, John B. Imboden³ and Xiaojuan Li⁴, ¹Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ²Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ³Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA, ⁴Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA
Background/Purpose: The goals of this project were (i) to develop novel quantitative and semiquantitative measures of bone erosions at the metacarpophalangeal (MCP) and wrist joints…
Abstract Number: 2585 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Versus Dual Energy Computed Tomography for Detection of Joint Pathology in Gout
Fiona M. McQueen¹, Anthony Doyle², Quentin Reeves³, Angela Gao³, Amy Tsai³, Gregory Gamble⁴, Barbara Curteis¹, Megan Williams⁵ and Nicola Dalbeth⁶, ¹Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Radiology, Auckland District Health Board, Auckland, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁶Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Magnetic resonance imaging (MRI) captures joint inflammation and damage in gouty arthropathy and can also reveal tophi. We have investigated reader reliability for scoring…
Abstract Number: 2546 • 2012 ACR/ARHP Annual Meeting
Tofacitinib Inhibits Radiographic Progression in Patients with Rheumatoid Arthritis Prone to Develop Structural Damage: A Post-Hoc Analysis of a Phase 3 Trial
Désirée van der Heijde¹, Robert B. M. Landewé² and David Gruben³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ³Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In the ORAL Scan trial…
Abstract Number: 2547 • 2012 ACR/ARHP Annual Meeting
Weekly Subcutaneous Abatacept Confers Comparable Onset of Treatment Response and Magnitude of Efficacy Improvement Over 6 Months When Administered with or without an Intravenous Abatacept Loading Dose
M. Schiff¹, R. Alten², M. Weinblatt³, P. Nash⁴, Roy Fleischmann⁵, P. Durez⁶, J. Kaine⁷, I. Delaet⁸, S. Kelly⁸, M. Maldonado⁸, S. Patel⁸ and M. C. Genovese⁹, ¹University of Colorado, Denver, CO, ²Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴University of Queensland, Brisbane, Australia, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Université Catholique de Louvain, Brussels, Belgium, ⁷Sarasota Arthritis Research Center, Sarasota, FL, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Stanford University, Palo Alto, CA
Background/Purpose: To compare clinical and functional responses with SC abatacept administered with or without an IV loading dose, in pts with active RA and inadequate…
Abstract Number: 2548 • 2012 ACR/ARHP Annual Meeting
Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients
Julie Ducreux¹, Adrien Nzeusseu Toukap², Frédéric A. Houssiau¹, Patrick Durez³ and Bernard Lauwerys³, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we…
Abstract Number: 2549 • 2012 ACR/ARHP Annual Meeting
Induction of Remission in Patients with up to 12 Months of Moderate-to-Severe Rheumatoid Arthritis Symptoms Treated with Etanercept Plus Methotrexate Over 52 Weeks
Paul Emery¹, Mohammed Hamoudeh², Oliver FitzGerald³, Bernard Combe⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Jack Bukowski⁶, Ronald Pedersen⁵, Andrew S. Koenig⁷ and Bonnie Vlahos⁵, ¹Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, ²Department of Medicine - Rheumatology, Hamad Medical Corporation, Doha, Qatar, ³Department of Rheumatology, St.Vincent's University Hospital, Dublin, Ireland, ⁴Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Pfizer, Inc., Collegeville, PA
Background/Purpose: In the COMET study, etanercept (ETN) plus methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA) yielded high clinical remission rates,1 but whether…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].